Anuh Pharma Ltd
Anuh Pharma Ltd Q2 FY26 Results & Presentation Highlights: Revenue, Margins & Order Book
Q2 FY26 investor presentation: what the company reported on revenue, margins and projects.
Based on Anuh Pharma Ltd's Q2 FY26 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the presentation reports, not management guidance.
The short version
Q2 FY 2025-26 (3 months ended 30/09/2025) Operating Revenue: Rs. EBITDA for the quarter ended 30/09/2025: Rs.
From Anuh Pharma Ltd's Q2 FY26 earnings-call transcript · updated 24 Sept 2026.
Revenue & Sales Performance
- Q2 FY 2025-26 (3 months ended 30/09/2025) Operating Revenue: Rs. 185.88 Cr, a -0.32% change quarter-on-quarter; 6 months ended 30/09/2025: Rs. 372.36 Cr, up 22.54% year-on-year from Rs. 303.86 Cr.
- Revenue for H1 FY 2025: Rs. 310.98 Cr; H1 FY 2026: Rs. 376.73 Cr, up 21.14% year-on-year.
- Domestic and export sales split shows growth: H1 FY26 total 371 Cr vs H1 FY25 total 302 Cr.
2 more points management made on revenue & sales performance
Profitability & Margins
See what Anuh Pharma Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Added a new intermediate block, increasing to 2 intermediate blocks and 9 API blocks, with total reactor capacity now at 240 KL. (Operational as of H1 FY26)
- Effluent treatment capacity increased from 100 KL/day to 150 KL/day to support higher production volumes. (Completed as of H1 FY26)
- Commissioned new solar power capacity to support cleaner energy use and reduce operational costs. (Completed as of H1 FY26)
2 more points management made on capital expenditure plans
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Anuh Pharma Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
2 more points management made on order book & pipeline
Anuh Pharma Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹202 Cr, net profit ₹12 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Anuh Pharma Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Morepen Laboratories Ltd (Q2 FY26)
248 Crores . Key investor presentation takeaways from Morepen Laboratories Ltd's Q2 FY26 investor presentation — and how it ranks against sector peers.
- Jubilant Pharmova Ltd (Q2 FY26)
Q2’FY26 revenue grew by 12% YoY to Rs. Key investor presentation takeaways from Jubilant Pharmova Ltd's Q2 FY26 investor presentation — and how it ranks against
- Themis Medicare Ltd (Q2 FY26)
Q2 FY26 Net Revenue: ₹77.99 Cr, down 33.3% YoY from ₹117.01 Cr in Q2 FY25 (Page 8) . Key investor presentation takeaways from Themis Medicare Ltd's Q2 FY26 inve
- Lincoln Pharmaceuticals Ltd (Q2 FY26)
EBITDA: ₹2,927 Crore, a YoY increase of 10.4% . Key investor presentation takeaways from Lincoln Pharmaceuticals Ltd's Q2 FY26 investor presentation — and how i
Frequently Asked Questions
What were Anuh Pharma Ltd Q2 FY26 results?
Q2 FY 2025-26 (3 months ended 30/09/2025) Operating Revenue: Rs. EBITDA for the quarter ended 30/09/2025: Rs.
What is Anuh Pharma Ltd share price analysis?
Anuh Pharma Ltd currently shows a neutral. The stock trades at a P/E of 21.2 with a market cap of ₹937 Cr. Investors should review the full earnings analysis for detailed insights.
Is Anuh Pharma Ltd planning capital expenditure?
Added a new intermediate block, increasing to 2 intermediate blocks and 9 API blocks, with total reactor capacity now at 240 KL.
Keep Anuh Pharma Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.